Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors

Post hoc analyses include data showing investigational oral semaglutide 25 mg use was associated with improvements in blood sugar control and cardiovascular (CV) risk factors across multiple categories of weight loss1 Another analysis detailed an indirect trial comparison between oral...